Biotech RadarJobs updated

COMPANY

Femasys

HQ: Suwanee, GA source · femasys.com ↗ · Southeast

FDA-cleared device company

Keywords: women's health Contraception Infertility Male Factor Fallopian Tube Patency Tests FemBloc FemBloc® Permanent Contraceptive System FemaSeed Localized Directional Insemination Sonography with FemVue, and HSG

Location: Suwanee, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$24.5MRaised (2 yrs)6Trials (company is sponsor)2FDA records (2 yrs)

Funding and NIH signals

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

  1. Partnership Partnership / licensing announced Jan 13, 2026. Source: company release on GlobeNewswire. source ↗
  2. FDA FDA 510(k) clearance: FemVue® Controlled Saline-Air Device (FSA-300) — K253403, Dec 15, 2025. Applicant at approval: Femasys, Inc. source ↗
  3. Raise Private placement: $12M (total, as published), announced Nov 3, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Nov 14, 2025 SEC Form D ↗
  4. Raise Follow-on offering: $8M (total, as published), announced Aug 26, 2025. Source: company release on GlobeNewswire. source ↗
  5. Partnership Partnership / licensing announced Jun 11, 2025. Source: company release on GlobeNewswire. source ↗
  6. Raise Follow-on offering: $4.5M (total, as published), announced May 30, 2025. Source: company release on GlobeNewswire. source ↗
  7. Partnership Partnership / licensing announced Mar 19, 2025. Source: company release on GlobeNewswire. source ↗
  8. Partnership Partnership / licensing announced Dec 3, 2024. Source: company release on GlobeNewswire. source ↗
  9. FDA FDA 510(k) clearance: FemVue MINI Saline-Air Device — K242002, Nov 22, 2024. Applicant at approval: Femasys, Inc. source ↗
  10. Partnership Partnership / licensing announced Oct 30, 2024. Source: company release on GlobeNewswire. source ↗
  11. Trial start Not phased (device or behavioral study): Prospective Multi-Center Trial for FemBloc Permanent Birth Control source ↗
  12. Trial start Not phased (device or behavioral study): FemaSeed LOCAL Artificial Insemination Trial source ↗
  13. Trial start Not phased (device or behavioral study): FemBloc® Permanent Contraception - Confirmation Feasibility Trial source ↗
  14. Trial start Not phased (device or behavioral study): FemBloc® Permanent Contraception - Early Pivotal Trial source ↗
  15. Trial start Not phased (device or behavioral study): Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception source ↗
  16. Trial start Not phased (device or behavioral study): Study of FemVue(TM) Sono Tubal Evaluation System Method Comparison to HSG source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $24.5M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT05977751Prospective Multi-Center Trial for FemBloc Permanent Birth ControlNot phased (device or behavioral study)RecruitingOct 31, 20232029-12 (estimated)
NCT03067272Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent ContraceptionNot phased (device or behavioral study)CompletedMar 15, 2017Feb 27, 2018 (actual)
NCT03433911FemBloc® Permanent Contraception - Early Pivotal TrialNot phased (device or behavioral study)CompletedFeb 2, 2018Jan 31, 2020 (actual)
NCT04273594FemBloc® Permanent Contraception - Confirmation Feasibility TrialNot phased (device or behavioral study)Active, not recruitingFeb 27, 2020Sep 30, 2022 (actual)
NCT04968847FemaSeed LOCAL Artificial Insemination TrialNot phased (device or behavioral study)CompletedJul 15, 2021Dec 31, 2023 (actual)
NCT01053052Study of FemVue(TM) Sono Tubal Evaluation System Method Comparison to HSGNot phased (device or behavioral study)Withdrawn2010-012013-01 (actual)

FDA records (last 2 years)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback